|
Director Takahiro Yamasaki |
|
Vice-director Taro Takami |
This center was established in March of 2005 as a dedicated facility for regenerative medicine. Since 2014, we have also been operating a processing facility that has the latest cell culture isolators.
In Japan, the field of regenerative medicine has seen dramatic advances in recent years. Our regenerative medicines are conducted in accordance with regulations and procedures for production control of regenerative medicine and related products as well as quality assurance and sanitation management practices that were revised in accordance with the Good Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP) ministerial ordinance issued in 2014. We thus strive to ensure all steps involved in cell processing are managed appropriately and to play one role in safe and effective regenerative medicine.
Regenerative medicine in FY2020
1, Cell processing for liver regeneration therapies using autologous bone marrow cells for patients with decompensated liver cirrhosis
2, Cell processing for treatment of refractory cutaneous ulcers with mixed sheets consisting of autologous peripheral blood mononuclear cells and fibroblasts
